Gastroenterology

FDA takes unprecedented step to spur OTC naloxone development





The FDA has, for the first time, proactively developed and tested a product label to encourage development of an over-the-counter version of the opioid overdose antidote naloxone, according to an agency statement.
The agency’s action removes the burden from the companies of creating such labels and conducting studies that show consumers can use a product without a health care professional’s supervision.
“Some stakeholders have identified the requirement to perform these studies as a barrier to development of OTC naloxone products,” Scott Gottlieb, MD, FDA commissioner,

Source link






Related posts

NASH resolves, fibrosis improves in 22% treated with growth factor analogue

Newsemia

FDA issues stronger constipation warning for clozapine

Newsemia

Liraglutide for management of adolescent obesity

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy